Avni Shah

Avni Shah is a Senior Scientist at Dragonfly Therapeutics, Inc., with a robust background in process development and analytical methods for drug products, particularly Antibody Drug Conjugates (ADCs). Prior to this role, Avni held positions at Intellia Therapeutics, Inc., and ImmunoGen, Inc., focusing on method development, stability testing, and IND filing support. Avni's early experience includes roles at Pfizer, EyeGate Pharmaceuticals, and a research assistantship at Northeastern University's Center for Pharmaceutical Biotechnology and Nanomedicine, where contributions were made to cancer research projects. Avni holds a Master's degree in Pharmaceutical Sciences and a Graduate Certificate in Biopharmaceutical Domestic Regulatory Affairs from Northeastern University.